The Low Density Lipoprotein Receptor Related Protein 5 pipeline drugs market research report outlays comprehensive information on the Low Density Lipoprotein Receptor Related Protein 5 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Low Density Lipoprotein Receptor Related Protein 5 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Ophthalmology, Gastrointestinal, Musculoskeletal Disorders, and Oncology which include the indications Diabetic Macular Edema, Diabetic Retinopathy, Inflammatory Bowel Disease, Bone Disorders, and Solid Tumor. It also reviews key players involved in Low Density Lipoprotein Receptor Related Protein 5 targeted therapeutics development with respective active and dormant or discontinued products.
The Low Density Lipoprotein Receptor Related Protein 5 pipeline targets constitutes close to five molecules. Out of which, approximately five molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase I, Preclinical, and Discovery stages are 1, 1, 1, and 2 respectively.
Low Density Lipoprotein Receptor Related Protein 5 overview
Low-Density Lipoprotein Receptor-Related Protein 5 (LRP5) is a transmembrane receptor protein that plays a crucial role in mediating Wnt signaling. LRP5 is a member of the low-density lipoprotein receptor family and is highly expressed in tissues with active cell proliferation and differentiation. LRP5 functions as a co-receptor for Wnt ligands, forming a complex with the Frizzled receptor. Upon Wnt binding, the LRP5/Frizzled complex activates downstream signaling cascades, leading to the stabilization and nuclear translocation of beta-catenin. In the nucleus, beta-catenin interacts with transcription factors, modulating the expression of target genes involved in cell fate determination, tissue development, and homeostasis. Mutations in the LRP5 gene have been associated with various human diseases. Loss-of-function mutations can lead to osteoporosis-pseudoglioma syndrome (OPPG), characterized by low bone mass and increased risk of fractures. On the other hand, gain-of-function mutations in LRP5 can result in high bone mass phenotypes, such as those observed in individuals with autosomal dominant high bone mass (HBM).
For a complete picture of Low Density Lipoprotein Receptor Related Protein 5’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
